Autres langues Spago Nanomedical AB

Actions

SPAG

SE0004899474

Marché Fermé - Nasdaq Stockholm Autres places de cotation 16:42:26 26/04/2024			Varia. 5j.	Varia. 1 janv.
0,36 ^SEK	+0,56 %		+8,76 %	+10,09 %

24/04	Spago Nanomedical AB (publ) annonce des résultats favorables dans un modèle de cancer du sein avec Tumorad	CI
16/04	Spago Nanomedical AB (publ) annonce la nomination de Birgitta Rembratt Svensson à la tête de CMC & Supply, à compter du 1er juin 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Spago Nanomedical AB Reports Favorable Data in Breast Cancer Model with Tumorad	24/04
Spago Nanomedical reports favorable data in breast cancer model with Tumorad	24/04
Spago Nanomedical strengthens management with Head of CMC and Supply	17/04
Spago Nanomedical strengthens management with Head of CMC & Supply	16/04
Spago Nanomedical AB Announces Appointment of Birgitta Rembratt Svensson as Head of CMC & Supply, Effective June 1, 2024	16/04
BioStock: Spago Nanomedical's CEO: "huge commercial opportunities are unfolding"	27/03
BioStock: 2023 springboard for Spago's radionuclide cancer therapy	09/02
Spago Nanomedical Q4 Update	08/02
Spago Nanomedical year-end report January-December, 2023	07/02
Spago Nanomedical AB Reports Earnings Results for the Full Year Ended December 31, 2023	07/02
Spago Nanomedical AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/02
The rights issue and the directed share issue to certain guarantors in Spago Nanomedical fully registered	25/01
Spago Nanomedical presents at Redeye's Fight Cancer event on January 24	19/01
Spago Nanomedical presents at Redeye’s Fight Cancer event on January 24	18/01
BioStock: Spago's phase I/IIa cancer trial progressing steadily	15/01
Spago Nanomedical Proceeds to the Next Dose Level in the Phase I/IIa Study Tumorad-01	10/01
Spago Nanomedical proceeds to the next dose level in the phase I/IIa study Tumorad-01	10/01
Spago Nanomedical - Update after funding and initiation of Tumorad	03/01
BioStock: Positive data in Spago's phase IIa endometriosis trial	20/12
Spago Nanomedical Announces Positive Top Line Data from a Clinical Phase IIa Study in Patients with Endometriosis	20/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Spago Nanomedical AB

Actions

SPAG

SE0004899474

Autres langues

Filtres